Investments | Biotech
The biotech company, Oxolife, raises 5 million euros for its Phase II Clinical Trial

Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Asset Management and the public body CDTI.